Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission

Basit Öğe Kaydı
dc.contributor.authorErdoğan, Mehmet
dc.contributor.authorÖzbek, Mustafa
dc.contributor.authorAkbal, Erdem
dc.contributor.authorÜreten, Kemal
dc.date.accessioned2020-12-01T12:36:45Z
dc.date.available2020-12-01T12:36:45Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground/aim: Acromegaly is associated with increased morbidity andmortality, mostly due to cardiovascular complications. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels are associated with coagulation/fibrinolysis and inflammation. Plasma TAFI may play a role in arterial thrombosis in cardiovascular diseases. in this study, it was aimed to evaluate the thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and homocysteine levels in patients with acromegaly and healthy control subjects. Materials and methods: Plasma TAFI antigen and homocysteine levels in 29 consecutive patients with acromegaly and 26 age-matched healthy control subjects were measured. All patients included in the study were in remission. the TAFIa/ai antigen in the plasma samples was measured using a commercially available ELISA kit. Results: Routine biochemical parameters, fasting blood glucose, prolactin, thyroid stimulating hormone, total-cholesterol, low density lipoprotein cholesterol, triglyceride, and homocysteine levels were similar in the 2 groups (P > 0.05), whereas the plasma TAFI antigen levels were significantly elevated in the acromegalic patients (154.7 ± 94.0%) when compared with the control subjects (107.2 ± 61.6%) (P = 0.033). No significant correlation was identified by Pearson’s correlation test between the plasma TAFI antigen and homocysteine levels (r = 0.320, P = 0.250). Conclusion: A significant alteration in the plasma TAFI antigen levels was detected in acromegaly. Increased plasma TAFI antigen levels might aggravate prothrombotic and thrombotic events in patients with acromegaly.en_US
dc.identifier.doi10.3906/sag-1812-231
dc.identifier.endpage1385en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue5en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1381en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1812-231
dc.identifier.urihttps://app.trdizin.gov.tr//makale/TXpNMk56SXdNQT09
dc.identifier.urihttps://hdl.handle.net/11454/67024
dc.identifier.volume49en_US
dc.identifier.wosWOS:000504050500017en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCerrahien_US
dc.titlePlasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remissionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu